Prognostic Differences of Adjuvant Radiotherapy in Breast Cancer Cohorts Based on <i>PRLR</i> Genotypes, Expression, and Transcriptional Network Regulation.

Cancers (Basel) · 2025 · PMC12293342 · PMID 40723262

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

The combined genotype 5 (AA/GG/TT/CC/TC) showed approximately a two-fold nominally significant increase in the incidence of new breast cancer events in both univariable and multivariable analyses (HR adj 1.90, 95% CI 1.08–3.35), without interaction terms ( Table 2 and Supplementary Table S5A ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Prognostic Differences of Adjuvant Radiotherapy in Breast Cancer Cohorts Based on &lt;i&gt;PRLR&lt;/i&gt; Genotypes, Expression, and Transcriptional Network Regulation.

The sentences

Prognostic Differences of Adjuvant Radiotherapy in Breast Cancer Cohorts Based on <i>PRLR</i> Genotypes, Expression, and Transcriptional Network Regulation.